Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2051-1426

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study ; volume:7 ; number:1 ; day:3 ; month:12 ; year:2019 ; pages:1-12 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (3.12.2019), 1-12, 12.2019

Creator: Manson, Guillaume
Maria, Alexandre Thibault Jacques
Poizeau, Florence
Danlos, François-Xavier
Kostine, Marie
Brosseau, Solenn
Aspeslagh, Sandrine
Rusquec, Pauline Du
Roger, Maxime
Pallix-Guyot, Maud
Ruivard, Marc
Dousset, Léa
Grignou, Laurianne
Psimaras, Dimitri
Pluvy, Johan
Quéré, Gilles
Grados, Franck
Duval, Fanny
Bourdain, Frederic
Maigne, Gwenola
Perrin, Julie
Godbert, Benoit
Taifas, Beatris Irina
Forestier, Alexandra
Voisin, Anne-Laure
Martin-Romano, Patricia
Baldini, Capucine
Marabelle, Aurélien
Massard, Christophe
Honnorat, Jérôme
Lambotte, Olivier
Michot, Jean-Marie

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40425-019-0821-8

URN: urn:nbn:de:101:1-2020032622163159150951

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Manson, Guillaume
Maria, Alexandre Thibault Jacques
Poizeau, Florence
Danlos, François-Xavier
Kostine, Marie
Brosseau, Solenn
Aspeslagh, Sandrine
Rusquec, Pauline Du
Roger, Maxime
Pallix-Guyot, Maud
Ruivard, Marc
Dousset, Léa
Grignou, Laurianne
Psimaras, Dimitri
Pluvy, Johan
Quéré, Gilles
Grados, Franck
Duval, Fanny
Bourdain, Frederic
Maigne, Gwenola
Perrin, Julie
Godbert, Benoit
Taifas, Beatris Irina
Forestier, Alexandra
Voisin, Anne-Laure
Martin-Romano, Patricia
Baldini, Capucine
Marabelle, Aurélien
Massard, Christophe
Honnorat, Jérôme
Lambotte, Olivier
Michot, Jean-Marie
SpringerLink (Online service)

Other Objects (12)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

Cancer immunotherapies targeting the PD-1 signaling pathway

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

Cancer immunotherapies targeting the PD-1 signaling pathway

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

Cancer immunotherapies targeting the PD-1 signaling pathway

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

Cancer immunotherapies targeting the PD-1 signaling pathway

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

Cancer immunotherapies targeting the PD-1 signaling pathway

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

Cancer immunotherapies targeting the PD-1 signaling pathway

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Related objects

Reset password